Nasdaq
$0.4035▼ 0.59%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $33.8MShares out 83.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
30- 6d agoPre-market26.10.19 22:228-KKey event#●●●#●●●#●●●
EyePoint, Inc.Bullish
EyePoint is terminating its Phase 3 LUCIA clinical trial for wet AMD early after the study failed to meet its primary endpoint. The company is implementing a strategic prioritization plan that includes a 53% workforce reduction and approximately $9 million in one-time charges, while shifting focus to its DME program to achieve $30 million in annualized savings.…more
$0.4035-0.59%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoPre-market26.10.19 20:058-KKey event
EyePoint, Inc.
EyePoint's Phase 3 LUCIA trial for DURAVYU in wet AMD failed to meet the primary endpoint of statistical non-inferiority in visual acuity compared to aflibercept. However, the drug met key secondary endpoints, demonstrating a 38% reduction in treatment burden and 52% supplement-free rates through Week 56 with a favorable safety profile. The company remains focused on its ongoing Phase 3 DME program, with topline data for the COMO and CAPRI trials expected in Q4 2027.…more
$0.4035-0.59%vs prev closeView filingShare - 10.7Pre-market26.10.07 20:22SCHEDULE 13G/AOwnership
EyePoint, Inc.
Federated Hermes affiliates have filed a joint Schedule 13G regarding their holdings in EyePoint, Inc. The reporting entities act as investment advisers with voting authority, but they expressly disclaim beneficial ownership of the reported securities.…more
$0.4035-0.59%vs prev closeView filingShare
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoRegular26.10.20 02:16Bullish#●●●#●●●#●●●
EyePoint Slashes Workforce by 53% and Halts Clinical Trials After Phase 3 Failure…more
EyePoint is cutting 53% of its workforce and halting its wet AMD clinical trials after failing to meet primary endpoints in a Phase 3 study. The company will now pivot its remaining resources toward its diabetic macular edema treatment program.…more
$0.4035-0.59%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 6d agoPre-market26.10.19 20:35
●●●●●●●● ●●●●● ●●●●●●
Trading for a specific stock was temporarily halted and has now resumed following a news announcement. Investors should review the latest company disclosures to assess the impact.…more
$0.4035-0.59%vs prev closeShareBenzinga - 6d agoPre-market26.10.19 20:15
●●●●●●●● ●●●●● ●●●●●●
EyePoint will terminate its wet AMD Phase 3 trials early after failing to meet the primary endpoint. To preserve capital, the company is reducing its workforce by 53% and shifting focus to its diabetic macular edema program.…more
$0.4035-0.59%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report